Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Treatment options for triple-negative breast cancer patients are limited, as patients are ineligible for treatment with either hormonal or HER2-targeted agents. Treatment typically involves nontargeted cytotoxic chemotherapies. Therefore, great commercial opportunity exists in developing effective, targeted therapies for this patient population. Interviewed oncologists are hopeful that more-effective targeted therapies are on the horizon for this patient population. However, the most promising emerging agents in development for triple-negative breast cancer target only specific subsets of patients, such as those with BRCA1/2 -mutation positive disease. As a result, the majority of the triple-negative breast cancer population is likely to remain underserved for the foreseeable future.
Attributes included in conjoint analysis based assessment of target product profiles for advanced/metastatic triple-negative breast cancer:
- Median overall survival.
- Progression-free survival.
- Overall response rate.
- Lymphopenia (grade 3/4).
- Neuropathy (grade 3/4).
- Thrombocytopenia (grade 3/4).
- Price per 21-day cycle.
Attributes included in assessment of U.S. payers’ receptivity to new therapies for advanced/metastatic triple-negative breast cancer:
- Effect on median overall survival.
- Effect on median progression-free survival.
- Effect on frequency of hematological toxicities.
- Effect on frequency of gastrointestinal toxicities.
Physicians surveyed: 60 U.S. and 30 European oncologists.
Payers surveyed: 20 U.S. MCO PDs.
Comprehensive List of Therapies Included in Our Research and Modeling:
- Nanoparticle paclitaxel (Celgene’s Abraxane)
- Paclitaxel (Bristol-Myers Squibb’s Taxol, generics)
- Paclitaxel + carboplatin (Bristol-Myers Squibb’s Taxol, generics plus Bristol-Myers Squibb’s Paraplatin, generics)
- Bevacizumab + paclitaxel (Roche/Genentech/Chugai’s Avastin plus Bristol-Myers Squibb’s Taxol, generics)
- Capecitabine (Roche/Chugai’s Xeloda, generics)
- Niraparib (Tesaro)
- Buparlisib (Novartis)
- Enzalutamide (Medivation’s Xtandi)
- Sorafenib + capecitabine (Bayer HealthCare/Onyx Pharmaceutical’s Nexavar plus Roche’s Xeloda, generics)
- Glembatumumab vedotin (Celldex Therapeutics)